Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection. The company's product candidate also include Lambda, which targets type III interferon receptors that has completed Phase II clinical trials; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide for the treatment of congenital hyperinsulinism, as well as has completed Phase II clinical trials to treat post-bariatric hypoglycemia. The company was founded in 2008 and is headquartered in Palo Alto, California.
IPO Year: 2014
Exchange: NASDAQ
Website: eigerbio.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/9/2021 | $26.00 → $27.00 | Buy | Citigroup |
4 - Eiger BioPharmaceuticals, Inc. (0001305253) (Issuer)
4 - Eiger BioPharmaceuticals, Inc. (0001305253) (Issuer)
Cutera, Inc. (NASDAQ:CUTR) ("Cutera" or the "Company"), a leading provider of aesthetic and dermatology solutions, is pleased to announce the appointment of Stephana Patton, Ph.D., J.D. as Chief Legal Officer, effective November 13, 2023. Dr. Patton will report directly to Taylor Harris, Cutera's Chief Executive Officer, and will be responsible for leading the legal, compliance, intellectual property and human resources functions. Dr. Patton brings over two decades of legal experience, focused on the life sciences industry both in private practice and as in-house counsel, to Cutera. Taylor Harris, Chief Executive Officer, said, "I am thrilled to welcome Stephana to the Cutera team. Step
PALO ALTO, Calif., May 3, 2023 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus (HDV) and other serious diseases, today reported that, in connection with the appointment of James A. Vollins as General Counsel, Chief Compliance Officer and Corporate Secretary, Eiger granted him a stock option to purchase 120,000 shares of Eiger's common stock. The stock option was approved by the Compensation Committee of Eiger's Board of Directors and granted under the Eiger BioPharmaceuticals, Inc. 2021 Inducement Plan, as amended, with a grant date of April 30, 2023, as an
PALO ALTO, Calif., Jan. 6, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure Hepatitis Delta Virus (HDV) and other serious diseases, today provided the company's outlook across multiple pipeline programs and operations, including planned 2022 catalysts and milestones. "This is a pivotal year for Eiger as we plan for topline data from the landmark D-LIVR study by year end. D-LIVR is the largest trial conducted in HDV and if positive will support re
PALO ALTO, Calif., Sept. 21, 2021 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced the appointment of Erik Atkisson as the Company's General Counsel and Chief Compliance Officer. Mr. Atkisson brings over twenty years of experience to Eiger, and was most recently Chief Compliance Officer, Legal Counsel, and Privacy Officer at Cytokinetics, Incorporated, where he was responsible for legal matter
PALO ALTO, Calif., April 22, 2021 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for serious rare and ultra-rare diseases, announced today the appointment of Kim Sablich to its Board of Directors. Ms. Sablich is a pharmaceutical industry veteran with broad commercial experience spanning over two decades in large pharma and biotechnology companies, including vaccines and prescription products across diverse therapeutic areas, and rare and ultra-rare disease programs. Ms. Sablich is currently Executive Vice President, General Manager, North America at Jazz Pharmaceuticals
8-K - Eiger BioPharmaceuticals, Inc. (0001305253) (Filer)
8-K - Eiger BioPharmaceuticals, Inc. (0001305253) (Filer)
10-K/A - Eiger BioPharmaceuticals, Inc. (0001305253) (Filer)
10-K - Eiger BioPharmaceuticals, Inc. (0001305253) (Filer)
8-K - Eiger BioPharmaceuticals, Inc. (0001305253) (Filer)
NT 10-K - Eiger BioPharmaceuticals, Inc. (0001305253) (Filer)
S-8 POS - Eiger BioPharmaceuticals, Inc. (0001305253) (Filer)
S-8 POS - Eiger BioPharmaceuticals, Inc. (0001305253) (Filer)
S-8 POS - Eiger BioPharmaceuticals, Inc. (0001305253) (Filer)
S-8 POS - Eiger BioPharmaceuticals, Inc. (0001305253) (Filer)
Prioritizing resources to advance avexitide in hyperinsulinemic hypoglycemia indicationsActive discussions underway with potential partners to advance late-stage virology programsReduction in workforce executed to align with focus on avexitide; extends cash runway to Q4 2024David Apelian, MD, PhD, MBA, appointed CEOLive conference call and webcast at 8:30 am ET todayPALO ALTO, Calif., June 29, 2023 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for rare diseases, today announced that following an extensive portfolio prioritization review, the Company will focus its development effor
Company to host conference call and live webcast on Thursday, June 29, at 8:30 am ETPALO ALTO, Calif., June 28, 2023 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for rare diseases, today announced that following an extensive portfolio prioritization exercise, the company will host a conference call and live webcast on Thursday, June 29, at 8:30 am ET. Conference Call Details The live and replayed webcast of the call will be available through the company's website at
Live Conference Call and Webcast at 8:30 AM ET PALO ALTO, Calif., Dec. 7, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus (HDV) and other serious diseases, today announced that it will host a conference call on Thursday, December 8, 2022, at 8:30 AM Eastern Time, to discuss the results of the Phase 3 D-LIVR study of lonafarnib-based treatments for HDV. The live and replayed webcast of the call will be available through the company's websi
Phase 3 HDV D-LIVR (lonafarnib-based regimens) Study Topline Data in DecemberPhase 3 HDV LIMT-2 (peginterferon lambda) Study Activating Sites and Enrolling PatientsPhase 3 Congenital Hyperinsulinism Avant (avexitide) Program InitiatedStrong Cash Position: $121.0 Million in Cash, Cash Equivalents, and Total InvestmentsPALO ALTO, Calif., Nov. 3, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus (HDV) and other serious diseases, today reported financial results for third quarter 2022 and provided a business update.
- Live Conference Call and Webcast at 4:30 PM ET - PALO ALTO, Calif., Oct. 24, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus (HDV) and other serious diseases, today announced that it will host a conference call on Thursday, November 3, 2022 at 4:30 PM ET to discuss its third quarter 2022 financial results and provide a business update. The live and replayed webcast of the call will be available through the company's website at www.eig
Active Dialogue with FDA on Potential Peginterferon Lambda COVID-19 EUA ApplicationPhase 3 HDV D-LIVR (lonafarnib) Study Topline Data Planned by Year EndPhase 3 Congenital Hyperinsulinism AVANT (avexitide) Program InitiatedApproval of Zokinvy in Europe; Partnership with AnGes in JapanStrong Cash Position: $141.8M Cash, Cash Equivalents, and Total InvestmentsPALO ALTO, Calif., Aug. 4, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus (HDV) infection and other serious diseases, today reported financial results for second quarter 2022 and provided a business
- Live Conference Call and Webcast at 4:30 PM ET - PALO ALTO, Calif., July 28, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus (HDV) and other serious diseases, today announced that it will host a conference call on Thursday, August 4, 2022 at 4:30 PM ET to discuss its second quarter 2022 financial results and provide a business update. The live and replayed webcast of the call will be available through the company's website at www.eig
Peginterferon lambda COVID-19 EUA Application to be Submitted in Q2 2022Phase 3 HDV D-LIVR (lonafarnib) Study Topline Data Anticipated by Year EndZokinvy® (lonafarnib) CHMP Opinion Expected in Q2 2022Phase 3 Avexitide Congenital Hyperinsulinism Program Initiation Planned by Year EndStrong Cash Position: $153.5M Pro Forma CashPALO ALTO, Calif., May 5, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure hepatitis delta virus (HDV) and other serious diseases, today reported financial results for first quarter 2022 and provided a business update.
- Live Conference Call and Webcast at 4:30 PM ET - PALO ALTO, Calif., April 21, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure hepatitis delta virus (HDV) and other serious diseases, today announced that it will host a conference call on Thursday, May 5, 2022 at 4:30 PM ET to discuss its first quarter 2022 financial results and provide a business update. The live and replayed webcast of the call will be available through the company's website
Second largest study to date in COVID-19 outpatients (N=1,936) Highly superior compared to placebo, with a probability of superiority of 99.91% on the primary endpoint 60% reduced risk of COVID-19-related death Primary endpoint achieved across multiple SARS-CoV-2 variants, including omicron Eiger plans to submit data to FDA for Emergency Use Authorization (EUA) Management to host conference call today at 8:30 AM ET PALO ALTO, Calif., March 17, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure Hepatitis Delta Virus (HDV) and other serious diseases, today announce
4 - Eiger BioPharmaceuticals, Inc. (0001305253) (Issuer)
4 - Eiger BioPharmaceuticals, Inc. (0001305253) (Issuer)
3 - Eiger BioPharmaceuticals, Inc. (0001305253) (Issuer)
3 - Eiger BioPharmaceuticals, Inc. (0001305253) (Issuer)
4 - Eiger BioPharmaceuticals, Inc. (0001305253) (Issuer)
3 - Eiger BioPharmaceuticals, Inc. (0001305253) (Issuer)
4 - Eiger BioPharmaceuticals, Inc. (0001305253) (Issuer)
4 - Eiger BioPharmaceuticals, Inc. (0001305253) (Issuer)
3 - Eiger BioPharmaceuticals, Inc. (0001305253) (Issuer)
3 - Eiger BioPharmaceuticals, Inc. (0001305253) (Issuer)
SC 13G/A - Eiger BioPharmaceuticals, Inc. (0001305253) (Subject)
SC 13G/A - Eiger BioPharmaceuticals, Inc. (0001305253) (Subject)
SC 13G/A - Eiger BioPharmaceuticals, Inc. (0001305253) (Subject)
SC 13D/A - Eiger BioPharmaceuticals, Inc. (0001305253) (Subject)
SC 13D - Eiger BioPharmaceuticals, Inc. (0001305253) (Subject)
SC 13D/A - Eiger BioPharmaceuticals, Inc. (0001305253) (Subject)
SC 13D - Eiger BioPharmaceuticals, Inc. (0001305253) (Subject)
SC 13G/A - Eiger BioPharmaceuticals, Inc. (0001305253) (Subject)
SC 13G - Eiger BioPharmaceuticals, Inc. (0001305253) (Subject)
SC 13G/A - Eiger BioPharmaceuticals, Inc. (0001305253) (Subject)
Citigroup reiterated coverage of Eiger BioPharmaceuticals with a rating of Buy and set a new price target of $27.00 from $26.00 previously
Announces "Stalking Horse" Agreement for the Sale of Zokinvy® (lonafarnib) Patient Access to Zokinvy® to Continue Uninterrupted PALO ALTO, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) today announced that it and its direct subsidiaries have filed voluntary petitions for chapter 11 protection under the United States Bankruptcy Code in the United States Bankruptcy Court for the Northern District of Texas. The company also announced a "stalking horse" agreement for the sale of Zokinvy® (lonafarnib) to Sentynl Therapeutics, Inc., a biopharmaceutical company focused on rare diseases. Under the terms of the "stalking horse" agreement, subject to court
Clinical trial data demonstrated Zokinvy treatment extended life by an average of 4.3 years in children and young adults with Hutchinson-Gilford progeriaEiger to receive $500,000 approval milestone payment from AnGesZokinvy approved in the U.S. (2020), 30 European countries (2022), and now Japan (2024)PALO ALTO, Calif., Jan. 18, 2024 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for rare metabolic diseases, today announced that it and its partner AnGes, Inc. received marketing approval from the Ministry of Health, Labour and Welfare for Zokinvy (lonafarnib), a treatment for Hutchin
PALO ALTO, Calif., Jan. 4, 2024 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) (the "Company"), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for rare metabolic diseases, today announced that it will conduct a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-30 (the "Reverse Stock Split"). The Reverse Stock Split will become effective at 11:59 p.m. Eastern Time, on January 5, 2024. The Company's common stock will begin trading on a post-split basis at the market open on January 8, 2024. The Reverse Stock Split is part of the Company's plan to regain compliance with the minimum bid price requireme
Cutera, Inc. (NASDAQ:CUTR) ("Cutera" or the "Company"), a leading provider of aesthetic and dermatology solutions, is pleased to announce the appointment of Stephana Patton, Ph.D., J.D. as Chief Legal Officer, effective November 13, 2023. Dr. Patton will report directly to Taylor Harris, Cutera's Chief Executive Officer, and will be responsible for leading the legal, compliance, intellectual property and human resources functions. Dr. Patton brings over two decades of legal experience, focused on the life sciences industry both in private practice and as in-house counsel, to Cutera. Taylor Harris, Chief Executive Officer, said, "I am thrilled to welcome Stephana to the Cutera team. Step
PALO ALTO, Calif., Sept. 12, 2023 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for rare metabolic diseases, today announced its decision to discontinue the Phase 3 LIMT-2 study of peginterferon lambda in patients with chronic hepatitis delta (CHD). The decision is based on the recommendation of the Data Safety Monitoring Board (DSMB) for the study following its quarterly safety review. In a communication dated September 7, 2023, the DSMB recommended the discontinuation of the LIMT-2 study due to observations of four patients with hepatobiliary events that resulted in liver decompe
PALO ALTO, Calif., Sept. 5, 2023 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for rare metabolic diseases, today announced that David Apelian, MD, PhD, MBA, CEO of Eiger, will present a company overview at the H.C. Wainwright 25th Annual Global Investment Conference on Monday, September 11, 2023 at 7:00 AM ET in New York, NY. Eiger will also host one-on-one meetings with investors at the conference. The presentation will be available on the Investors section of the
Resources prioritized to advance avexitide in hyperinsulinemic hypoglycemia indicationsActive discussions underway with potential partners to advance late-stage virology programsReduction in workforce executed to align with focus on avexitide; extends cash runway into Q4 2024David Apelian, MD, PhD, MBA, appointed CEOPALO ALTO, Calif., Aug. 14, 2023 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for rare metabolic diseases, today reported financial results for the second quarter 2023 and provided a business update.
Prioritizing resources to advance avexitide in hyperinsulinemic hypoglycemia indicationsActive discussions underway with potential partners to advance late-stage virology programsReduction in workforce executed to align with focus on avexitide; extends cash runway to Q4 2024David Apelian, MD, PhD, MBA, appointed CEOLive conference call and webcast at 8:30 am ET todayPALO ALTO, Calif., June 29, 2023 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for rare diseases, today announced that following an extensive portfolio prioritization review, the Company will focus its development effor
Company to host conference call and live webcast on Thursday, June 29, at 8:30 am ETPALO ALTO, Calif., June 28, 2023 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for rare diseases, today announced that following an extensive portfolio prioritization exercise, the company will host a conference call and live webcast on Thursday, June 29, at 8:30 am ET. Conference Call Details The live and replayed webcast of the call will be available through the company's website at
Phase 3 HDV D-LIVR (lonafarnib/ritonavir) Study: Pre-NDA Meeting with FDA in Q2Phase 3 HDV LIMT-2 (peginterferon lambda) Study: Complete Randomization in Q2Phase 3 HI AVANT (avexitide) Program: Startup Activities InitiatedCash Position: $75.3 million in Cash, Cash Equivalents, and Short-Term Debt Securities as of March 31, 2023PALO ALTO, Calif., May 11, 2023 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus (HDV) and other serious diseases, today reported financial results for first quarter 2023 and provided a business update.